Tenax Therapeutics, Inc. - Common Stock (NQ:TENX)

1.640 -0.170 (-9.39%)

Delayed Quote Updated: 3:15 PM EST, Nov 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Tenax Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

Deadline Alert: Tenax Therapeutics, Inc. Stockholders Face December 28, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

Today 13:00 EST

From The Law Offices of Howard G. Smith

Via Business Wire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

November 04, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Deadline Alert: Tenax Therapeutics, Inc. Shareholders Have Until December 28, 2026 to Seek Lead Plaintiff Appointment in Securities Fraud Lawsuit, The Law Offices of Frank R. Cruz Notes

November 04, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Did You Lose Money Investing in Tenax Therapeutics, Inc.? Robbins LLP Urges Investors with Large Losses to Contact the Firm for Information About Their Rights Against TENX

November 04, 2026

San Diego, California--(Newsfile Corp. - November 4, 2026) - Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased...

Via Newsfile

Topics Lawsuit

Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX

November 03, 2026

From Pomerantz LLP

Via GlobeNewswire

Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

November 03, 2026

From The Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

November 03, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

SueWallSt Reminds Tenax Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of December 28, 2026 - TENX

November 03, 2026

A securities fraud class action puts the Tenax promise-reality gap on the record. Management pointed to a 29-meter Phase 2 walk result, while the lawsuit claims TNX-103 was less effective than...

From SueWallSt

Via GlobeNewswire

Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

November 02, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

TENX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Tenax Therapeutics Securities Lawsuit - Contact Levi & Korsinsky

November 02, 2026

Important Information Regarding Section 20(a) Individual Liability Claims: Tenax's chief executive and three successive chief financial officers face control person claims over allegedly misleading...

From Levi & Korsinsky, LLP

Via GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

November 01, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

TENX Shareholder Alert: December 28, 2026 Lead Plaintiff Deadline in Tenax Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

October 30, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop

October 30, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 89.77% Share Price Decline

October 30, 2026

From The Law Offices of Howard G. Smith

Via Business Wire

TENX INVESTOR DEADLINE: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit

October 29, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

October 29, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 89.77% Stock Decline

October 29, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Rosen Law Firm Urges Tenax Therapeutics, Inc. (NASDAQ: TENX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

October 28, 2026

From Rosen Law Firm

Via Business Wire

Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX

October 27, 2026

From Pomerantz LLP

Via GlobeNewswire

Investor Alert: Robbins LLP Informs Investors of the Tenax Therapeutics, Inc. Class Action Lawsuit

October 27, 2026

From Robbins LLP

Via Business Wire

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

August 16, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

August 14, 2026

From Levi & Korsinsky, LLP

Via Business Wire

Tenax Therapeutics Inc. (NASDAQ: TENX) Near the Top of Equities by Percentage Gain on 2/6

February 06, 2024

Via Investor Brand Network

InvestorNewsBreaks – Tenax Therapeutics Inc. (NASDAQ: TENX) Announces $15.6M Public Offering

February 10, 2023

Via Investor Brand Network

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 02, 2023

Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and

Via Spotlight Growth

Topics Intellectual Property

Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

May 25, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 23, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

May 18, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

March 31, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

March 30, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.